Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Red Biotechnology Market Set for Robust Growth Through 2035, Fueled by Precision Medicine, Gene Therapies and Biopharmaceutical Innovation

globenewswire.com
PFE Pfizer Inc. is listed as a key participant in the red biotechnology market, which is projected for robust growth. The article does not provide specific sentiment towards Pfizer's individual performance or outlook. BIIB Biogen Inc. is identified as a key player in the growing red biotechnology market. The article does not offer specific details or sentiment regarding Biogen's performance. AMGN Amgen Inc. is mentioned as a key participant in the red biotechnology market, which is expected to experience significant growth. The article does not provide specific sentiment for Amgen. AZN AstraZeneca Plc. is listed as a key participant in the red biotechnology market, which is projected for robust growth. The article does not provide specific sentiment towards AstraZeneca's individual performance or outlook. GILD Gilead Sciences, Inc. is identified as a key player in the red biotechnology market. The article does not offer specific sentiment or performance details for Gilead. MRK Merck KGaA is listed as a key participant in the red biotechnology market. The article does not offer specific sentiment or performance details for Merck KGaA. BMY Bristol-Myers Squibb Company is identified as a key player in the red biotechnology market. The article does not provide specific sentiment or performance details for Bristol-Myers Squibb. REGN Regeneron Pharmaceuticals Inc. is mentioned as a key participant in the red biotechnology market, which is projected for growth. The article does not provide specific sentiment for Regeneron. LLY Eli Lilly's acquisition of Kelonia Therapeutics and previous acquisitions highlight its strategic importance and aggressive pipeline strengthening in the cell and gene therapy segment, indicating a strong bullish outlook. NVS Novartis's acquisition of Avidity Biosciences moving toward completion suggests a positive strategic move and confidence in the gene therapy sector, contributing to a bullish sentiment. BMRN BioMarin Pharmaceutical's acquisition of Amicus Therapeutics indicates strategic investment and confidence in the rare disease and gene therapy space, supporting a bullish sentiment. AMTX Amicus Therapeutics is being acquired by BioMarin Pharmaceutical, which is a significant event. However, the article does not provide specific sentiment on Amicus's individual performance or future outlook beyond the acquisition.

Red Biotechnology Market Set for Robust Growth Through 2035, Fueled by Precision Medicine, Gene Therapies and Biopharmaceutical Innovation Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Red Biotechnology Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)" has been added to ResearchAndMarkets.com's offering.

The global red biotechnology market was valued at USD 410.54 million in 2025 and is projected to reach USD 749.20 million by 2035. The market is expected to expand at a compound annual growth rate (CAGR) of 6.20% during the 2026-2035 forecast period, driven by innovation in biopharmaceutical production, gene therapy, genetic testing and precision medicine.

Rising demand for advanced treatments, growing awareness of therapies for chronic diseases and a strong pipeline of therapeutic candidates are supporting global market growth. Increased healthcare investment, continued pharmaceutical research and the expanding use of biotechnology in oncology and rare disease treatment are also strengthening the outlook for the red biotechnology industry.

Latest Red Biotechnology Market News

April 2026: Eli Lilly Acquires Kelonia Therapeutics

Eli Lilly's acquisition of in vivo cell therapy developer Kelonia Therapeutics highlights the growing strategic importance of cell and gene therapy assets within global pharmaceutical pipelines. The transaction represented at least the sixth acquisition in the segment since March 2025 and was reported as the largest by total potential proceeds during that period.

The deal followed other Eli Lilly transactions, including the acquisition of Ajax and its clinical-stage myelofibrosis therapy. This activity reflects the pharmaceutical industry's efforts to strengthen product pipelines ahead of an estimated USD 170 billion patent cliff, which is expected to intensify competition for innovative biotechnology platforms and clinical-stage therapies.

March 2026: Novartis-Avidity Biosciences Transaction Moves Toward Completion

Novartis's USD 12 billion acquisition of Avidity Biosciences advanced toward an anticipated closing in the first half of 2026. The transaction followed BioMarin Pharmaceutical's USD 4.8 billion agreement to acquire Amicus Therapeutics, announced on December 19, 2025.

Improved clarity surrounding U.S. healthcare policy and additional interest-rate reductions have contributed to a more supportive environment for biotechnology investment and mergers and acquisitions. Industry analysts have consequently identified 2026 as a potentially significant investment period for red biotechnology, particularly across gene therapy, cell therapy and rare disease portfolios.

Red Biotechnology Market Size and Forecast

Market Segmentation by Application

Biopharmaceutical production remains a major application segment, supported by demand for innovative biologic medicines and targeted treatments. Gene therapy is also expected to gain momentum as clinical research advances and pharmaceutical companies increase investment in next-generation therapeutic platforms. Pharmacogenomics and genetic testing are benefiting from the wider adoption of precision medicine and more individualized treatment strategies.

Market Segmentation by End Use

Pharmaceutical companies represent an important source of demand due to expanding research pipelines, clinical trials and commercialization programs. Contract manufacturing and research organizations are also gaining prominence as drug developers outsource specialized development, testing and production activities. Research institutes continue to support innovation through studies focused on cancer, genetic disorders, regenerative medicine and other complex diseases.

Regional Market Coverage

North America and Europe remain central to red biotechnology research, financing and commercialization, supported by established pharmaceutical industries and extensive clinical development capabilities. Asia Pacific presents additional growth opportunities as healthcare expenditure rises, biotechnology infrastructure expands and regional governments promote life sciences research and domestic drug production.

Market Growth Drivers

The global red biotechnology market is benefiting from increasing demand for gene therapies, clinical research and advanced treatment platforms. Growing cancer prevalence is accelerating the use of biotechnology in disease research, therapeutic development and biomarker identification. Stem cell banking and regenerative medicine applications are also contributing to market expansion as awareness and access improve.

At the same time, increased healthcare funding and pharmaceutical investment are enabling companies to advance new molecules through preclinical and clinical development. Strategic acquisitions, research collaborations and licensing agreements are expected to remain important competitive tools throughout the forecast period.

Competitive Landscape

The global red biotechnology market includes major pharmaceutical and biotechnology companies focused on product innovation, pipeline development, manufacturing capacity and strategic transactions. Key market participants include:

Competitive assessment of the red biotechnology industry covers company capabilities, pipeline activity, capacity expansions, operational developments, mergers and acquisitions, and strategic partnerships. The market outlook also incorporates SWOT analysis and Porter's Five Forces analysis to evaluate competitive intensity, supplier and buyer dynamics, barriers to entry and the potential impact of substitute technologies.

Key Topics Covered:

1 Preface

2 Report Coverage - Key Segmentation and Scope

3 Report Description

3.1 Market Definition and Outlook

3.2 Properties and Applications

3.3 Market Analysis

3.4 Key Players

4 Key Assumptions

5 Executive Summary

5.1 Overview

5.2 Key Drivers

5.3 Key Developments

5.4 Competitive Structure

5.5 Key Industrial Trends

6 Snapshot

6.1 Global

6.2 Regional

7 Opportunities and Challenges in the Market

8 Global Red Biotechnology Market Analysis

8.1 Key Industry Highlights

8.2 Global Red Biotechnology Historical Market (2019-2025)

8.3 Global Red Biotechnology Market Forecast (2026-2035)

8.4 Global Red Biotechnology Market by Application

8.4.1 Biopharmaceutical Production

8.4.1.1 Historical Trend (2019-2025)

8.4.1.2 Forecast Trend (2026-2035)

8.4.2 Gene Therapy

8.4.2.1 Historical Trend (2019-2025)

8.4.2.2 Forecast Trend (2026-2035)

8.4.3 Pharmacogenomics

8.4.3.1 Historical Trend (2019-2025)

8.4.3.2 Forecast Trend (2026-2035)

8.4.4 Genetic Testing

8.4.4.1 Historical Trend (2019-2025)

8.4.4.2 Forecast Trend (2026-2035)

8.5 Global Red Biotechnology Market by End-use

8.5.1 Pharmaceutical Industry

8.5.1.1 Historical Trend (2019-2025)

8.5.1.2 Forecast Trend (2026-2035)

8.5.2 CMO & CRO

8.5.2.1 Historical Trend (2019-2025)

8.5.2.2 Forecast Trend (2026-2035)

8.5.3 Research Institutes

8.5.3.1 Historical Trend (2019-2025)

8.5.3.2 Forecast Trend (2026-2035)

8.5.4 Others

8.6 Global Red Biotechnology Market by Region

8.6.1 North America

8.6.1.1 Historical Trend (2019-2025)

8.6.1.2 Forecast Trend (2026-2035)

8.6.2 Europe

8.6.2.1 Historical Trend (2019-2025)

8.6.2.2 Forecast Trend (2026-2035)

8.6.3 Asia Pacific

8.6.3.1 Historical Trend (2019-2025)

8.6.3.2 Forecast Trend (2026-2035)

8.6.4 Latin America

8.6.4.1 Historical Trend (2019-2025)

8.6.4.2 Forecast Trend (2026-2035)

8.6.5 Middle East and Africa

8.6.5.1 Historical Trend (2019-2025)

8.6.5.2 Forecast Trend (2026-2035)

9 North America Red Biotechnology Market Analysis

9.1 United States of America

9.1.1 Historical Trend (2019-2025)

9.1.2 Forecast Trend (2026-2035)

9.2 Canada

9.2.1 Historical Trend (2019-2025)

9.2.2 Forecast Trend (2026-2035)

10 Europe Red Biotechnology Market Analysis

10.1 United Kingdom

10.1.1 Historical Trend (2019-2025)

10.1.2 Forecast Trend (2026-2035)

10.2 Germany

10.2.1 Historical Trend (2019-2025)

10.2.2 Forecast Trend (2026-2035)

10.3 France

10.3.1 Historical Trend (2019-2025)

10.3.2 Forecast Trend (2026-2035)

10.4 Italy

10.4.1 Historical Trend (2019-2025)

10.4.2 Forecast Trend (2026-2035)

10.5 Others

11 Asia Pacific Red Biotechnology Market Analysis

11.1 China

11.1.1 Historical Trend (2019-2025)

11.1.2 Forecast Trend (2026-2035)

11.2 Japan

11.2.1 Historical Trend (2019-2025)

11.2.2 Forecast Trend (2026-2035)

11.3 India

11.3.1 Historical Trend (2019-2025)

11.3.2 Forecast Trend (2026-2035)

11.4 ASEAN

11.4.1 Historical Trend (2019-2025)

11.4.2 Forecast Trend (2026-2035)

11.5 Australia

11.5.1 Historical Trend (2019-2025)

11.5.2 Forecast Trend (2026-2035)

11.6 Others

12 Latin America Red Biotechnology Market Analysis

12.1 Brazil

12.1.1 Historical Trend (2019-2025)

12.1.2 Forecast Trend (2026-2035)

12.2 Argentina

12.2.1 Historical Trend (2019-2025)

12.2.2 Forecast Trend (2026-2035)

12.3 Mexico

12.3.1 Historical Trend (2019-2025)

12.3.2 Forecast Trend (2026-2035)

12.4 Others

13 Middle East and Africa Red Biotechnology Market Analysis

13.1 Saudi Arabia

13.1.1 Historical Trend (2019-2025)

13.1.2 Forecast Trend (2026-2035)

13.2 United Arab Emirates

13.2.1 Historical Trend (2019-2025)

13.2.2 Forecast Trend (2026-2035)

13.3 Nigeria

13.3.1 Historical Trend (2019-2025)

13.3.2 Forecast Trend (2026-2035)

13.4 South Africa

13.4.1 Historical Trend (2019-2025)

13.4.2 Forecast Trend (2026-2035)

13.5 Others

14 Market Dynamics

14.1 SWOT Analysis

14.1.1 Strengths

14.1.2 Weaknesses

14.1.3 Opportunities

14.1.4 Threats

14.2 Porter's Five Forces Analysis

14.2.1 Supplier's Power

14.2.2 Buyer's Power

14.2.3 Threat of New Entrants

14.2.4 Degree of Rivalry

14.2.5 Threat of Substitutes

14.3 Key Indicators for Demand

14.4 Key Indicators for Price

15 Value Chain Analysis

16 Competitive Landscape

16.1 Market Structure

16.2 Company Profiles

16.2.1 Pfizer Inc.

16.2.1.1 Company Overview

16.2.1.2 Product Portfolio

16.2.1.3 Demographic Reach and Achievements

16.2.1.4 Certifications

16.2.2 Biogen Inc.

16.2.2.1 Company Overview

16.2.2.2 Product Portfolio

16.2.2.3 Demographic Reach and Achievements

16.2.2.4 Certifications

16.2.3 Amgen Inc.

16.2.3.1 Company Overview

16.2.3.2 Product Portfolio

16.2.3.3 Demographic Reach and Achievements

16.2.3.4 Certifications

16.2.4 Astrazeneca Plc.

16.2.4.1 Company Overview

16.2.4.2 Product Portfolio

16.2.4.3 Demographic Reach and Achievements

16.2.4.4 Certifications

16.2.5 Gilead Sciences, Inc.

16.2.5.1 Company Overview

16.2.5.2 Product Portfolio

16.2.5.3 Demographic Reach and Achievements

16.2.5.4 Certifications

16.2.6 F. Hoffmann-La Roche, Ltd.

16.2.6.1 Company Overview

16.2.6.2 Product Portfolio

16.2.6.3 Demographic Reach and Achievements

16.2.6.4 Certifications

16.2.7 Merck KGaA

16.2.7.1 Company Overview

16.2.7.2 Product Portfolio

16.2.7.3 Demographic Reach and Achievements

16.2.7.4 Certifications

16.2.8 Bristol-Myers Squibb Company

16.2.8.1 Company Overview

16.2.8.2 Product Portfolio

16.2.8.3 Demographic Reach and Achievements

16.2.8.4 Certifications

16.2.9 Regeneron Pharmaceuticals Inc.

16.2.9.1 Company Overview

16.2.9.2 Product Portfolio

16.2.9.3 Demographic Reach and Achievements

16.2.9.4 Certifications

16.2.10 Others

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/r37ayf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.